Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Staffing Up For More Biopharma Merger Oversight

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency's 2011 budget request seeks to expand staff to monitor "increasingly complex" mergers and an "active merger enforcement agenda" in pharma and other key markets.

You may also be interested in...

FTC, Energized By Androgel, Presses For Patent Settlement Ban

In the swirling alliances of the health care reform debate, a press conference by FTC and House Democrats features a consumer who feels he was harmed by the deal between Solvay and generic firms.

Pharma Industry Watchdog Brill Nominated For FTC Commissioner

Julie Brill, as Vermont's Assistant Attorney General, headed state efforts to have drug companies disclose payments to physicians and to restrict use of data on physician prescribing habits for marketing.

FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts